Search Results

NSC 319726 1mg  | ≥98%

CSNpharm

NSC319726 is a mutant p53R175 reactivator inhibiting growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM) and showing no inhibition for p53 wild-type cells.

More Information Supplier Page

NSC 319726 5mg  | ≥98%

CSNpharm

NSC319726 is a mutant p53R175 reactivator inhibiting growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM) and showing no inhibition for p53 wild-type cells.

More Information Supplier Page

NSC 319726 10mg  | ≥98%

CSNpharm

NSC319726 is a mutant p53R175 reactivator inhibiting growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM) and showing no inhibition for p53 wild-type cells.

More Information Supplier Page

NSC 319726 50mg  | ≥98%

CSNpharm

NSC319726 is a mutant p53R175 reactivator inhibiting growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM) and showing no inhibition for p53 wild-type cells.

More Information Supplier Page

Go6983 50mg  | ≥99%

CSNpharm

Go6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively and less potent to PKCζ and inactive to PKCμ.

More Information Supplier Page

Go6983 100mg  | ≥99%

CSNpharm

Go6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively and less potent to PKCζ and inactive to PKCμ.

More Information Supplier Page

HMN-214 10mg  | ≥99%

CSNpharm

HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

More Information Supplier Page